Illustrative image – not actual.
Gland Pharma has drawn up a capital expenditure plan of Rs 800 crore for FY23. This includes Rs 300 crore towards a new biotech vaccine facility.
The pharma company expects to supply the Russian Sputnik vaccines made in India by the end of 2021.
The company is expanding capacities with new lines and setting up a new R&D centre at the Pashamylaram facility in Hyderabad, Telangana. To scale up the backward integration, it is expanding its API capacity at the Vizag facility by adding a new block.
